Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Executive Changes Strategy Biosimilars

Bieber Becomes Biopharmaceuticals Development Head At Sandoz

  • News

Executive Summary

Florian Bieber is to become head of development for Sandoz’ biopharmaceuticals division, after Mark Levick agreed to take up the post of CEO at Alvotech.

You may also be interested in...



Sandoz Biopharma Head Levick To Become CEO Of Alvotech

Mark Levick, Sandoz’ head of development for biopharmaceuticals, has been chosen to become CEO of Alvotech from August.

Slowing Biopharmaceuticals Puts A Dent In Sandoz’ Sales

Slower sales growth by its Biopharmaceuticals unit amid competitive pressures in the US, combined with weakness in its Retail Generics and Anti-Infectives franchises, led Sandoz to report an overall 8% sales slide in the first quarter of this year. 

Novartis Selects GSK’s Saynor As Next Sandoz CEO

GlaxoSmithKline’s established products head, Richard Saynor, will return to Sandoz later this year to lead the Novartis division.

Table

View full table

Topics

Related Companies

Tags:
Executive Changes Strategy Biosimilars
Latest Headlines

What’s Next? Five Things To Look Out For In October

Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma

Shortlist Revealed Ahead Of October Awards

Teva Looks To Novartis To Replace Departing Dethlefs

See All
UsernamePublicRestriction

Register

GB140327

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By